Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.03 | 3.99 | 260.83 |
| FCF Yield | -81.77% | -4.65% | -0.61% | -0.01% |
| EV / EBITDA | 0.13 | -20.57 | -214.78 | -17,491.36 |
| Quality | ||||
| ROIC | -92.40% | -85.66% | -56.52% | -42.06% |
| Gross Margin | 23.07% | 38.97% | 88.91% | 0.00% |
| Cash Conversion Ratio | 0.47 | 0.87 | 0.89 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 44.45% | 24.83% | -31.87% | -94.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | 0.13 | 1.08 | 1.93 |
| Interest Coverage | 0.00 | 0.00 | -521.18 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.92 | 0.34 | -0.12 | -8.14 |
| Cash Conversion Cycle | 467.35 | 1,013.65 | -5,874.65 | -121.98 |